NCT07154810View on ClinicalTrials.gov

Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination

Active, not recruitingOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

April 14, 2031

Study Completion Date

April 14, 2031

Conditions
GlaucomaCataractOcular Hypertension
Trial Locations (1)

41101

Centro Oftalmológico Robles, Santa Rosa de Copán

All Listed Sponsors
lead

SpyGlass Pharma, Inc.

INDUSTRY